Contact Us
  • AF Detection At a Dual-Chamber Level, No Unnecessary Burden

    DX Technology offers AF detection at a dual-chamber level without the atrial lead¹- providing a less invasive alternative that shortens procedure time² and reduces complication risk.3,4,5

  • Giving Control Back to the Patient's Autonomic Nervous System

    Closed Loop Stimulation (CLS) mimics the natural sinus node function by responding to ANS signals - helping reduce atrial burden to slow AF progression.6,7,8,9

Dual-Chamber-Level AF Detection, No Unnecessary Burden

DX Technology offers dual-chamber-level AF detection without the atrial lead¹- providing a less invasive alternative that shortens procedure time² and reduces complication risk.3,4,5

BIOTRONIK is the only company to offer true atrial sensing in a single-lead ICD.

Atrial leads in ICD patients without atrial pacing needs add unnecessary complication risks - yet remain common. This issue affects >50% of primary prevention patients in the U.S.³

heart
  • Single-lead ICD systems offer significantly lower complication risks.3,4
  • DX has demonstrated significant procedural efficiency gains, reflected in 15% shorter procedure times and 28% shorter lead implantation times²
  • In 2025, a large, multi-center study involving 1,329 ICD patients confirmed that DX ICDs effectively detect subclinical AF at the dual-chamber level, over a maximum follow-up of 6 years¹
  • In that study, 98.7% of DX ICD patients did not require an atrial lead upgrade.¹
  • CRT-DX has been shown to reduce major complications by 50%.5

Giving Back Control to the Patient's Autonomic Nervous System

Closed Loop Stimulation (CLS) mimics the natural sinus node function by responding to ANS signals - helping reduce atrial burden to slow AF progression.6,7,8,9

Patients requiring atrial pacing can benefit from physiologic heart rate modulation. CLS responds to myocardial contractility, driven by the ANS.
Only available in BIOTRONIK devices.

  • CLS is the only algorithm that showed a reduction in the incidence of subclinical AF in sinus node disease patients (16% lower risk)9
  • 27% relative risk reduction of subclinical AF in patients without history of AF9
  • 23% relative risk reduction of subclinical AF in patients without AV block9
  • Multiple studies have shown that physiologic rate adaptation achieved by CLS can reduce atrial burden6,7,8

Pacing the heart's natural conduction system has been at the forefront of CRM in recent years. But the goal of true physiologic pacing doesn't stop at the conduction system; it also requires physiologic heart rate.

CLS image
quality_icon

Leading in ICD Quality

Our commitment to quality is at our core. We manufacture all critical components ourselves - in the U.S., Germany and Singapore. The result: Zero open ICD recalls in the U.S. as per the FDA database.¹²

quality_img

We are driven by clinically meaningful innovation - but it holds true value only when paired with uncompromising product quality. That is why BIOTRONIK invests significant time and resources in our quality management program.

At BIOTRONIK, we pursue excellence in every detail.

  • We manufacture all critical device components in countries considered quality capitals of the world
  • Our vertically integrated corporate structure allows us to leverage our deep technological expertise through the entire product development and production cycle
  • Among ICD manufacturers in the U.S., only BIOTRONIK has zero open ICD recalls as per the FDA database¹²
  • Award-Winning MRI Technology

    BIOTRONIK's unique MRI AutoDetect is a sensor that minimizes the patient's time in non-physiological MRI pacing mode and streamlines workflows - earning the CardioStim Innovation Award.

  • Clinically Impactful Home Monitoring

    We pioneered Home Monitoring®, the first remote monitoring solution for ICDs. It demonstrated its clinical impact in the IN-TIME study, achieving over 60% reduction in mortality through daily monitoring.10

Award-Winning MRI Technology

BIOTRONIK's unique MRI AutoDetect is a sensor that minimizes the patient's time in non-physiological MRI pacing mode and streamlines workflows - earning the CardioStim Innovation Award.

We know patient well-being goes beyond cardiac health, and MRI access can be key for accurate, and sometimes lifesaving, diagnoses.

BIOTRONIK ICDs are equipped with MRI AutoDetect, a sensor that enables automatic switching into MRI mode – and back.

  • Reduces the patient’s time in non-physiological MRI pacing mode to the minimum
  • Removes unnecessary MRI workflow burden
  • Winner of the CardioStim Innovation Award for Best Practice Improvement
CardioStim Innovation Award

Clinically Impactful Home Monitoring

We pioneered Home Monitoring®, the first remote monitoring solution for ICDs. It demonstrated its clinical impact in the IN-TIME study, achieving over 60% reduction in mortality through daily monitoring.10

60% all-cause mortality reduction

Did you know that BIOTRONIK developed the world's first remote monitoring solution for ICD patients?

BIOTRONIK believed in the clinical impact of continuously monitoring patients' heart and device status. Therefore, we developed Home Monitoring (HM) - and pushed further by conducting the IN-TIME study.10

  • World's first remote monitoring solution for ICDs patients in the industry
  • To date, only BIOTRONIK has been able to show >60% mortality reduction for heart failure patients with daily remote monitoring10
  • HM has demonstrated a 52% reduction of inappropriate ICD shocks and 72% reduction of hospitalization due to inappropriate shocks11
  • Mitacchione G, Curnis A, Celentano E, et al. New-Onset Device-Detected Atrial Fibrillation in Patients With Atrial Floating Dipole Implantable Cardioverter-Defibrillators: A Propensity Score-Matched Comparison With Conventional Dual-Chamber Systems. J Cardiovasc Electrophysiol. 2025 Jun;36(6):1303-1313. doi: 10.1111/jce.16666.
  • Sticherling C, Zabel M, Spencker S, et al. Comparison of a novel, single-lead atrial sensing system with a dual-chamber implantable cardioverter-defibrillator system in patients without antibradycardia pacing indications: results of a randomized study. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):56-63. doi: 10.1161/CIRCEP.110.958397.
  • Margolis G, et al. “Single- versus dual-chamber implantable cardioverter-defibrillator for primary prevention of sudden cardiac death in the United States" J Am Heart Assoc. 2023;12:e029126. doi: 10.1161/JAHA.122.029126.
  • Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol. 2011 Aug 30;58(10):1007-13. doi: 10.1016/j.jacc.2011.04.039.
  • Shaik NA, Drucker M, Pierce C, et al. Novel two-lead cardiac resynchronization therapy system provides equivalent CRT responses with less complications than a conventional three-lead system: Results from the QP ExCELs lead registry. J Cardiovasc Electrophysiol. 2020 Jul;31(7):1784-1792. doi: 10.1111/jce.14552.
  • Ikeda S, Nogami A, Inoue K, et al. Closed-loop stimulation as a physiological rate-modulated pacing approach based on intracardiac impedance to lower the atrial tachyarrhythmia burden in patients with sinus node dysfunction and atrial fibrillation. J Cardiovasc Electrophysiol. 2020 May;31(5):1187-1194. doi: 10.1111/jce.14430.
  • Puglisi A, Favale S, Scipione P, et al; Burden II Study Group. Overdrive versus conventional or closed-loop rate modulation pacing in the prevention of atrial tachyarrhythmias in Brady-Tachy syndrome: on behalf of the Burden II Study Group. Pacing Clin Electrophysiol. 2008 Nov;31(11):1443-55. doi: 10.1111/j.1540-8159.2008.01208.x.
  • Puglisi A, Altamura G, Capestro F, et al. Impact of Closed-Loop Stimulation, overdrive pacing, DDDR pacing mode on atrial tachyarrhythmia burden in Brady-Tachy Syndrome. A randomized study. Eur Heart J. 2003 Nov;24(21):1952-61. doi: 10.1016/j.ehj.2003.08.011.
  • Pisanò ECL, Calvi V, Viscusi Met al. Closed Loop Stimulation reduces the incidence of atrial high-rate episodes compared to conventional rate-adaptive pacing in patients with sinus node dysfunctions. Europace. 2024 Jun 28:euae175. doi: 10.1093/europace/euae175.
  • Hindricks G, Taborsky M, Glikson M, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet. 2014 Aug 16;384(9943):583-590. doi: 10.1016/S0140-6736(14)61176-4.
  • Guédon-Moreau L, Lacroix D, Sadoul N, et al. A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trial. Eur Heart J. 2013 Feb;34(8):605-14. doi: 10.1093/eurheartj/ehs425.
  • Source: FDA database on device recalls, accessed December 2024.